Showing results (21-30 of 142) with videos related to

Sort By:
Pageof 15
Acute Medicine & Surgery|May 10, 2021
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency departmentKatsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2013
Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastasesTakaaki Tokito, Takehito Shukuya, Hiroaki Akamatsu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancerThomas John, Hiroaki Akamatsu, Angelo Delmonte, et al.
Clinical Lung Cancer|May 29, 2021
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 InhibitorsJun Oyanagi, Yasuhiro Koh, Koichi Sato, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2024
Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancerYuichi Ozawa, Yasuhiro Koh, Ryota Shibaki, et al.
BMC Cancer|September 25, 2023
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, et al.
Cancer Science|April 27, 2018
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trialHiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, et al.
Respirology Case Reports|August 20, 2024
Can FDG-PET after neoadjuvant chemotherapy plus nivolumab predict residual disease in non-small cell lung cancer?Hideto Iguchi, Hiroaki Akamatsu, Yoshimitsu Hirai, et al.
BMC Cancer|November 8, 2022
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomesKoichi Sato, Hiroaki Akamatsu, Yasuhiro Koh, et al.
Clinical Lung Cancer|September 30, 2018
A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)Hiroaki Akamatsu, Hideyuki Harada, Shoji Tokunaga, et al.
Pageof 15